EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Can-Fite BioPharma Ltd (CANF) fair value: what the stock is really worth

As of Oct 8, 2026: fair value of Can-Fite BioPharma Ltd ILS 3.93, price ILS 3.10, upside +26.8%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · Il · ISIN IL0010944739

CF Can-Fite BioPharma Ltd logo Thin data Oct 3, 2026

Can-Fite BioPharma Ltd

CANF · TA

SpeculativeUpside exists, but weak quality makes the signal speculative.

Fair value 3.93 ILA · Undervalued (+26.8%)
Quality 41/100
Weak Growth (revenue 5y −10.5 %/yr in ILA)
Negative free cash flow
Trails peers (2/7)
Narrow moat 3/100 · thin data
Thin data
Watch Can-Fite BioPharma Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

771.00 ILA 3.10 ILA Fair Value 3.93 ILA May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 3.10 ILA – 771.00 ILA · fair‑value band 2.60 ILA – 4.92 ILA · the 3.10 ILA price screens below the 3.93 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Can-Fite BioPharma in your weekly email

Every Wednesday you see whether Can-Fite BioPharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.

Show more

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, It offers cannabinoids for treatment of conditions associated with elevated expression of the A3 adenosine receptors. Further, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Stock analysis

Can-Fite BioPharma Ltd (CANF) currently trades at 3.10 ILA, while our model-based Fair Value estimate is 3.93 ILA, implying the stock looks roughly 21.1% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 2.60 ILA (bear) to 4.92 ILA (bull), the price of 3.10 ILA sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Can-Fite BioPharma Ltd reported revenue of $438K in FY2025 versus $853K in FY2021, a compound −15.3%/yr. Reported net income was −$10.6M in FY2025.

Key figures

Market cap 14.1M ILA · P/S ratio 54.0 · EPS (TTM) −16.03 ILA · Return on equity −178% · Return on assets (EBIT) −91.3% · Operating margin −2,489% · Revenue (TTM) 405K ILA · Revenue growth (YoY) −43.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 90% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 27%, CANF screens cheaper than that median.

Fair Value models

Bear 2.60 ILA Fair Value 3.93 ILA Bull 4.92 ILA
Price 3.10 ILA · Upside +26.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2.00 ILA 2.68 ILA 3.99 ILA 51
All 1 models by family
Asset-Based
NCAV (Graham) 2.00 ILA 2.68 ILA 3.99 ILA 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

Of which business quality 41 · Market factors (momentum, volatility) 15

Profitability 2
Margins and returns on capital today
Quality Growth 7
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 72
Balance sheet, leverage, solvency risk
Investment 86
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−35.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.5%
Start year 2020 (pandemic). Over 10 years: +10.3% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−16.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,853.1% (2020) → −2,456.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CANF, get fair value alerts →

Compare Can-Fite BioPharma Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 591 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside +26.8% · Top 25%
Profitability
Return on assets −66.8% · Bottom 25%
Growth and dividend
Revenue growth −43.3% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.83× · Cheaper than median
P/S (TTM) 11.41× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)69 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73% vs CANF
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10% vs CANF
Samsung Biologics Co 207940 1,219,000 KRW 1,340,900 KRW +10% vs CANF
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10% vs CANF
CSL Limited CSL A$181.46 A$179.90 −1% vs CANF
argenx SE ARGX $959.49 $918.60 −4% vs CANF
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15% vs CANF
BeOne Medicines AG ONC $360.85 $280.94 −22% vs CANF
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58% vs CANF
Royalty Pharma plc RPRX $58.21 $19.01 −67% vs CANF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Can-Fite BioPharma Ltd · Fair Value
3.93 ILA +21%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Can-Fite BioPharma Ltd Fair Value". https://www.fairvalue-calculator.com/stock/CANF

Frequently asked questions

Is Can-Fite BioPharma Ltd (CANF) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 3.93 ILA versus a price of 3.10 ILA, about +27% upside (undervalued).
What is the fair value of CANF?
Our model-based fair value for Can-Fite BioPharma Ltd is 3.93 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 3.10 ILA.
What is the quality score of CANF?
Can-Fite BioPharma Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Can-Fite BioPharma Ltd (CANF)?
Our model-based price target is the fair value of 3.93 ILA (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 2.60 ILA, optimistic scenario 4.92 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Can-Fite BioPharma Ltd stock forecast for 2026?
Our models put fair value at 3.93 ILA, about +27% upside versus a price of 3.10 ILA (undervalued). Cautious scenario 2.60 ILA, optimistic scenario 4.92 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Can-Fite BioPharma Ltd (CANF)?
Can-Fite BioPharma Ltd reported trailing-twelve-month revenue of about 405K ILS (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Can-Fite BioPharma Ltd (CANF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Can-Fite BioPharma Ltd it is 3.93 ILA per share (as of Oct 3, 2026), against a price of 3.10 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Can-Fite BioPharma Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, CANF trades below its calculated fair value: price 3.10 ILA, fair value 3.93 ILA, a gap of about +27% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CANF?
No. The price is what the market pays today (3.10 ILA); the fair value is what the company's own numbers justify (3.93 ILA). For Can-Fite BioPharma Ltd the two are 0.8300 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Can-Fite BioPharma Ltd worth?
The market values Can-Fite BioPharma Ltd at about 14.1M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 3.10 ILA; our models calculate a fair value of 3.93 ILA per share.
What do the bullish and bearish scenarios say about CANF?
Our models span a range for Can-Fite BioPharma Ltd: cautious scenario 2.60 ILA, base 3.93 ILA, optimistic 4.92 ILA per share (as of Oct 3, 2026, price 3.10 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Can-Fite BioPharma Ltd (CANF)?
Balance-sheet figures for Can-Fite BioPharma Ltd (as of Oct 3, 2026): return on equity −178.2%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is CANF from its 52-week high?
Can-Fite BioPharma Ltd trades at 3.10 ILA, about 90% below its 52-week high of 30.00 ILA and at the low of 3.10 ILA (as of Oct 8, 2026). Distance from the high says nothing about value: that is what the fair value of 3.93 ILA is for.
Which stocks are comparable to Can-Fite BioPharma Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Can-Fite BioPharma Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price 3.10 ILA, calculated fair value 3.93 ILA (+27%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CANF calculated?
We run Can-Fite BioPharma Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.93 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Can-Fite BioPharma Ltd currently trades 21 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Can-Fite BioPharma Ltd (CANF)?
The closing price on Oct 8, 2026 was 3.10 ILA. Our model-based fair value is 3.93 ILA, about +27% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Can-Fite BioPharma Ltd right now?
A fairly wide model range (2.60 ILA to 4.92 ILA) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Can-Fite BioPharma Ltd

How large is the market capitalisation of Can-Fite BioPharma Ltd (CANF)?
The market capitalisation of Can-Fite BioPharma Ltd is 14.1M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Can-Fite BioPharma Ltd (CANF)?
The price-to-sales ratio of Can-Fite BioPharma Ltd is 54.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Can-Fite BioPharma Ltd (CANF)?
Earnings per share at Can-Fite BioPharma Ltd are −16.03 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Can-Fite BioPharma Ltd (CANF)?
The return on equity (ROE) of Can-Fite BioPharma Ltd is −178% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Can-Fite BioPharma Ltd (CANF)?
On an EBIT basis the return on assets of Can-Fite BioPharma Ltd is −91.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Can-Fite BioPharma Ltd (CANF)?
The operating margin of Can-Fite BioPharma Ltd is −2,489% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Can-Fite BioPharma Ltd (CANF)?
Revenue at Can-Fite BioPharma Ltd is growing −43.3% versus a year earlier (3y avg −18.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Can-Fite BioPharma Ltd (CANF) generate?
The free cash flow of Can-Fite BioPharma Ltd is −9.7M ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Can-Fite BioPharma Ltd (CANF) hold?
Can-Fite BioPharma Ltd holds more cash than debt, 5.5M ILA net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Can-Fite BioPharma Ltd in the live analysis

One click puts Can-Fite BioPharma Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.